Cubist exec Perez joins AMAG Pharmaceuticals board

By Mass High Tech staff

Cubist files IP lawsuit against Teva [March 24, 2009]

Forma partners with Singapore anti-cancer drugs [March 16, 2009]

Cubist and Forma Therapeutics form a multi-million dollar deal [January 26, 2009]

AMAG Pharma’s CKD diagnostics on FDA Fast Track [August 21, 2008]

Cambridge biotech firm AMAG Pharmaceuticals Inc. has named Cubist Pharmaceuticals Inc. executive Robert J. Perez to its board of directors.

AMAG (Nasdaq: AMAG) is developing treatment for anemia and diagnostic tools for cancer and cardiovascular disease. Its product candidate Fereheme is intended for use as an intravenous iron replacement therapeutic agent to treat iron deficiency anemia and as a diagnostic tool in assessing arterial disease.

Perez is executive vice president and COO of Cubist Pharmaceuticals (Nasdaq: CBST), handling business development, commercial and technical operations and information technology. He also led the development of Cubicin, Cubist’s treatment for methicillin-resistant Staphylococcus aureus (MRSA).

Before he joined Cubist in 2003, Perez served most recently as vice president-CNS business unit at Biogen Inc., where he managed the $800 million commercial development of the company’s neurology business department. Prior to spending nine years at Biogen, Perez also worked at Zeneca Pharmaceuticals. Perez graduated from The Anderson School at UCLA with an MBA and from California State University, Los Angeles, with a bachelor of science degree.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.